Autism Spectrum Disorders Market Growth, Trends, and Oppotunities 2031

MARKET INTRODUCTION

Autism Spectrum Disorder (ASD) is a group of neurological conditions, which hampers developmental of social interaction, communication and use of verbal and non-verbal language. The exact cause is still unknown. People with autism have issues in carrying out regular activities. Children with autism have issues during social interaction. Social interaction and communication are the core impairments of ASD, whereas, seizures, sensory issues, anxiety, sleep deficits, self-injury and others are associated symptoms. There is no definitive treatment for the treatment of core symptoms yet, however, the FDA have approved many drugs for associated symptoms. For instance, antipsychotics such as risperidone and aripripazole are used in treating irritability associated with disorder.

MARKET DYNAMICS

The autism spectrum disorders market is anticipated to grow in the forecast period owing to the increasing research and development for discovery of novel therapies. Growing pipeline for the autism spectrum disorder is one of the prime factors for the growth of the market. There is no current therapies for the treatment of autism spectrum disorders, which have increased number of untreated population. For instance, autism prevalence has increased by 15% in children, affecting 1 out of 59 children, the CDC. Moreover, increasing government efforts to increasing knowledge regarding autism is boosting the growth of the market. For instance, in August 2021, the Centers for Disease Control and Prevention announced to invest USD 27 million in the next five years to conduct the Study to Explore Early Development (SEED). This is one of the largest studies in the U.S., which will help in identifying risk factors in children for autism spectrum disorder (ASD).

MARKET SCOPE

The "Global Autism Spectrum Disorders Market Analysis to 2031" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of autism spectrum disorders market with detailed market segmentation by type, treatment type and geography. The global autism spectrum disorders market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading autism spectrum disorders market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global autism spectrum disorders market is segmented on the basis of type, and treatment type. Based on type, the market is segmented as autistic disorder, pervasive developmental disorder, Asperger syndrome and others. Based on treatment type, the market is segmented as drug therapy and communication & behavioral therapy.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Autism Spectrum Disorders market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The autism spectrum disorders market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting autism spectrum disorders market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the autism spectrum disorders market in these regions.

MARKET PLAYERS

The report covers key developments in the autism spectrum disorders market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from autism spectrum disorders market are anticipated to lucrative growth opportunities in the future with the rising demand for autism spectrum disorders market in the global market. Below mentioned is the list of few companies engaged in the autism spectrum disorders market.

The report also includes the profiles of key autism spectrum disorders market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

•  F. Hoffmann-La Roche AG
•  Nobelpharma Co., Ltd.
•  Johnson & Johnson
•  Yamo Pharmaceuticals
•  Curemark
•  Servier
•  Neurochlore

Pipeline Analysis

Many companies are engaged in the development of autism spectrum disorders drugs, which are currently in the pipeline. Some of the major brands are F. Hoffmann-La Roche AG, Nobelpharma Co., Ltd., Johnson & Johnson, Yamo Pharmaceuticals, Curemark, Servier, Neurochlore among others.
Some of the major pipeline drugs are mentioned below:
- In 2021, Roche's received breakthrough therapy designation for balovaptan in autism spectrum disorder from the FDA. Balovaptan is expected to be first pharmacotherapy, which will help in improving core social interaction and communication in patients
- In 2021, Yamo Pharmaceuticals, LLC, received Fast Track Designation for L1-79, which is a tyrosine hydroxylase inhibitor. This will help in reducing the socialization and communication symptoms in patients suffering with autism spectrum disorder (ASD)
- In May 2021, Finch Therapeutics received fast track designation by the FDA for its Full-Spectrum Microbiota, or FSM therapy for children with autism spectrum disorder
- In June 2021, Q BioMed Inc., which is commercial stage biotech company, filed for Orphan Drug designation for QBM-001. This product is being designed to treat pediatric minimally verbal autism (PVMA)

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Autism Spectrum Disorders Report Scope